Corpora Amylacea in the Human Brain Exhibit Neoepitopes of a Carbohydrate Nature

dc.contributor.authorRiba Baqués, Marta
dc.contributor.authorAugé Marí, Elisabet
dc.contributor.authorTena, Iraida
dc.contributor.authorValle i Macià, Jaume del
dc.contributor.authorMolina Porcel, Laura
dc.contributor.authorXimelis, Teresa
dc.contributor.authorVilaplana i Hortensi, Jordi
dc.contributor.authorPelegrí i Gabaldà, Carme
dc.date.accessioned2021-07-15T11:48:47Z
dc.date.available2021-07-15T11:48:47Z
dc.date.issued2021-06-28
dc.date.updated2021-07-15T11:48:47Z
dc.description.abstractCorpora amylacea (CA) in the human brain are polyglucosan bodies that accumulate residual substances originated from aging and both neurodegenerative and infectious processes. These structures, which act as waste containers, are released from the brain to the cerebrospinal fluid, reach the cervical lymph nodes via the meningeal lymphatic system and may be phagocytosed by macrophages. Recent studies indicate that CA present certain neoepitopes (NEs) that can be recognized by natural antibodies of the IgM class, and although evidence of different kinds suggests that these NEs may be formed by carbohydrate structures, their precise nature is unknown. Here, we adapted standard techniques to examine this question. We observed that the preadsorption of IgMs with specific carbohydrates has inhibitory effects on the interaction between IgMs and CA, and found that the digestion of CA proteins had no effect on this interaction. These findings point to the carbohydrate nature of the NEs located in CA. Moreover, the present study indicates that, in vitro, the binding between certain natural IgMs and certain epitopes may be disrupted by certain monosaccharides. We wonder, therefore, whether these inhibitions may also occur in vivo. Further studies should now be carried out to assess the possible in vivo effect of glycemia on the reactivity of natural IgMs and, by extension, on natural immunity.
dc.format.extent16 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec713200
dc.identifier.issn1664-3224
dc.identifier.pmid34262556
dc.identifier.urihttps://hdl.handle.net/2445/179111
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3389/fimmu.2021.618193
dc.relation.ispartofFrontiers in Immunology, 2021, vol. 12, num. 618193, p. 1-16
dc.relation.urihttps://doi.org/10.3389/fimmu.2021.618193
dc.rightscc-by (c) Riba Baqués, Marta et al., 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Bioquímica i Fisiologia)
dc.subject.classificationEnvelliment
dc.subject.classificationMalalties neurodegeneratives
dc.subject.classificationMetabolisme
dc.subject.classificationImmunologia
dc.subject.classificationSistema limfàtic
dc.subject.classificationSistema immunitari
dc.subject.classificationFagocitosi
dc.subject.otherAging
dc.subject.otherNeurodegenerative Diseases
dc.subject.otherMetabolism
dc.subject.otherImmunology
dc.subject.otherLymphatics
dc.subject.otherImmune system
dc.subject.otherPhagocytosis
dc.titleCorpora Amylacea in the Human Brain Exhibit Neoepitopes of a Carbohydrate Nature
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
713200.pdf
Mida:
9.94 MB
Format:
Adobe Portable Document Format